Potentially actionable pharmacogenetic variants and symptom control medications in oncology.

Jai Narendra PatelDanielle BoselliElizabeth J JandrisevitsIssam S HamadehAhmed SalemPatrick MeadorsDeclan Walsh

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)

About half presented with significant symptom burden, which highly correlated with SCM prescribing. Most received SCMs with PGx evidence. Preemptive PGx testing for these variants should be evaluated in prospective trials to evaluate the impact on symptom control.

Keyphrases

copy number
patient reported
primary care
emergency department
risk factors